NASDAQ:VBLT

Vascular Biogenics - VBLT Stock Forecast, Price & News

$0.15

0.00 (-1.91%)

(As of 09/27/2022 04:11 PM ET)

Add

Compare

Today's Range: $0.15
▼
$0.16
50-Day Range: $0.15
▼
$2.05
52-Week Range: $0.15
▼
$2.54

Volume: 958,136 shs
Average Volume: 1.53 million shs
Market Capitalization: $10.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.88

Vascular Biogenics MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 3,171.8% Upside
$4.88 Price Target
Short Interest: Healthy
0.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.48) to ($0.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

952nd out of 1,071 stocks

Pharmaceutical Preparations Industry

461st out of 531 stocks

3.1

Analyst's Opinion

Consensus Rating
Vascular Biogenics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.88, Vascular Biogenics has a forecasted upside of 3,171.8% from its current price of $0.15.
Amount of Analyst Coverage
Vascular Biogenics has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.20% of the float of Vascular Biogenics has been sold short.
Short Interest Ratio / Days to Cover
Vascular Biogenics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vascular Biogenics has recently decreased by 82.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vascular Biogenics does not currently pay a dividend.
Dividend Growth
Vascular Biogenics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VBLT.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Vascular Biogenics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for VBLT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Vascular Biogenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vascular Biogenics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 8.54% of the stock of Vascular Biogenics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Vascular Biogenics are expected to grow in the coming year, from ($0.48) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vascular Biogenics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vascular Biogenics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vascular Biogenics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Stock News Headlines

September 24, 2022 | americanbankingnews.com

Vascular Biogenics (NASDAQ:VBLT) Receives New Coverage from Analysts at StockNews.com

September 18, 2022 | americanbankingnews.com

Vascular Biogenics (NASDAQ:VBLT) Earns Sell Rating from Analysts at StockNews.com

September 2, 2022 | finance.yahoo.com

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

September 1, 2022 | finance.yahoo.com

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

September 1, 2022 | finance.yahoo.com

Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

August 2, 2022 | marketwatch.com

Vascular Biogenics Cutting About 35% of Staff >VBLT

August 2, 2022 | finance.yahoo.com

VBL Therapeutics Announces Workforce Reduction

July 21, 2022 | finance.yahoo.com

Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails

July 20, 2022 | msn.com

Gold Prices Settle Lower; Vascular Biogenics Shares Plummet

July 20, 2022 | msn.com

Why Is Vascular Biogenics (VBLT) Stock Down 80% Today?

July 20, 2022 | finance.yahoo.com

Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low

July 19, 2022 | finance.yahoo.com

VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

May 31, 2022 | finance.yahoo.com

VBL Therapeutics to Participate in the Jefferies Healthcare Conference

May 10, 2022 | finance.yahoo.com

VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

May 8, 2022 | finance.yahoo.com

What Kind Of Shareholders Hold The Majority In Vascular Biogenics Ltd.'s (NASDAQ:VBLT) Shares?

May 3, 2022 | finance.yahoo.com

VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May

April 26, 2022 | msn.com

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell ...

April 16, 2022 | seekingalpha.com

Vascular Biogenics (VBLT) Presents at the KOL Event on Ovarian Cancer - Slideshow

March 23, 2022 | finance.yahoo.com

VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

March 22, 2022 | benzinga.com

Vascular Biogenics Earnings Preview

March 22, 2022 | markets.businessinsider.com

Vascular Biogenics earnings: here's what Wall Street expects

March 14, 2022 | finance.yahoo.com

UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23

March 8, 2022 | marketwatch.com

Vascular Biogenics Shares Rise Premarket on Phase 3 Ofra-Vec Study Update >VBLT

March 8, 2022 | finance.yahoo.com

VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

March 3, 2022 | finance.yahoo.com

VBL Therapeutics to Participate at March Investor Conferences

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings: 8/15/2022
Today: 9/27/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VBLT
Previous Symbol: NASDAQ:VBLX
CUSIP: N/A
CIK: 1603207
Web: www.vblrx.com
Phone: (728) 993-5000
Fax: 972-8993-5001
Employees: 41
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.88
High Stock Price Forecast: $5.50
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +3,169.6%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,920,000.00
Net Margins: -6,201.22%
Pretax Margin: -6,201.22%
Return on Equity: -80.16%
Return on Assets: -62.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.05
Quick Ratio: 4.05

Sales & Book Value

Annual Sales: $770,000.00
Price / Sales: 13.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.73 per share
Price / Book: 0.20

Miscellaneous

Outstanding Shares: 69,327,000
Free Float: N/A
Market Cap: $10.34 million
Optionable: Optionable
Beta: 0.56

Key Executives

Prof. Dror Harats M.D. (Age 65)
CEO & Director

Dr. Eyal Breitbart Ph.D. (Age 55)
Sr. VP of Research & Operations

Dr. Naamit Sher Ph.D. (Age 68)
Sr. VP of Drug Devel. & Regulatory Affairs

Dr. Erez Feige M.B.A. (Age 48)
Ph.D., Sr. VP of Bus. Operations

Mr. Amos Ron (Age 67)
Company Sec.

Mr. Samuel Backenroth (Age 38)
Chief Financial Officer

Advocate Ayelet Horn (Age 51)
Gen. Counsel

Deborah Scott
Managing Director of Financial Communications

Dr. Tami Rachmilewitz M.D. (Age 52)
Sr. VP of Clinical Devel.

Mr. Matthew Trudeau M.Sc.
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VBLT Stock - Frequently Asked Questions

Should I buy or sell Vascular Biogenics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View VBLT analyst ratings or view top-rated stocks.
What is Vascular Biogenics' stock price forecast for 2022?: 4 Wall Street analysts have issued 1-year price targets for Vascular Biogenics' shares. Their VBLT share price forecasts range from $4.00 to $5.50. On average, they predict the company's stock price to reach $4.88 in the next year. This suggests a possible upside of 3,126.3% from the stock's current price.
View analysts price targets for VBLT or view top-rated stocks among Wall Street analysts.
How have VBLT shares performed in 2022?: Vascular Biogenics' stock was trading at $1.97 on January 1st, 2022. Since then, VBLT shares have decreased by 92.3% and is now trading at $0.1511.
View the best growth stocks for 2022 here.
When is Vascular Biogenics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our VBLT earnings forecast.
How were Vascular Biogenics' earnings last quarter?: Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its quarterly earnings data on Monday, August, 15th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.15 million. Vascular Biogenics had a negative net margin of 6,201.22% and a negative trailing twelve-month return on equity of 80.16%.

What other stocks do shareholders of Vascular Biogenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).
What is Vascular Biogenics' stock symbol?: Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."
Who are Vascular Biogenics' major shareholders?: Vascular Biogenics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Caption Management LLC (0.20%) and Group One Trading L.P. (0.00%).
How do I buy shares of Vascular Biogenics?: Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vascular Biogenics' stock price today?: One share of VBLT stock can currently be purchased for approximately $0.15.
How much money does Vascular Biogenics make?: Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $10.48 million and generates $770,000.00 in revenue each year. The biopharmaceutical company earns $-29,920,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.
How can I contact Vascular Biogenics?: Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vascular Biogenics - VBLT Stock Forecast, Price & News

Vascular Biogenics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month